Prothena Past Earnings Performance
Past criteria checks 0/6
Prothena has been growing earnings at an average annual rate of 3%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 45.8% per year.
Key information
3.0%
Earnings growth rate
9.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 45.8% |
Return on equity | -26.2% |
Net Margin | -160.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Feb 23Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%
Feb 08Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?
Dec 20Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business
Nov 24Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk
Oct 27Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Aug 25What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today
May 10We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth
Apr 23Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook
Mar 01We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate
Dec 28Prothena: Paying A Premium To Cover All The Alzheimer's Bases
Sep 29Prothena GAAP EPS of -$0.88 misses by $0.31
Aug 08Bearish: Analysts Just Cut Their Prothena Corporation plc (NASDAQ:PRTA) Revenue and EPS estimates
May 08Are Prothena Corporation plc (NASDAQ:PRTA) Investors Paying Above The Intrinsic Value?
Jan 10Prothena: A Biotech Company With A Promising Pipeline
Dec 01Revenue & Expenses BreakdownBeta
How Prothena makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 91 | -147 | 62 | 0 |
30 Sep 23 | 141 | -73 | 58 | 0 |
30 Jun 23 | 58 | -141 | 53 | 0 |
31 Mar 23 | 55 | -128 | 52 | 0 |
31 Dec 22 | 54 | -117 | 50 | 0 |
30 Sep 22 | 5 | -156 | 49 | 0 |
30 Jun 22 | 143 | -1 | 49 | 0 |
31 Mar 22 | 202 | 67 | 47 | 0 |
31 Dec 21 | 201 | 67 | 46 | 0 |
30 Sep 21 | 200 | 69 | 44 | 0 |
30 Jun 21 | 61 | -70 | 41 | 0 |
31 Mar 21 | 1 | -124 | 40 | 0 |
31 Dec 20 | 1 | -111 | 39 | 0 |
30 Sep 20 | 1 | -102 | 37 | 0 |
30 Jun 20 | 1 | -91 | 36 | 0 |
31 Mar 20 | 1 | -80 | 36 | 0 |
31 Dec 19 | 1 | -78 | 36 | 0 |
30 Sep 19 | 1 | -79 | 36 | 0 |
30 Jun 19 | 1 | -84 | 36 | 0 |
31 Mar 19 | 1 | -128 | 38 | 0 |
31 Dec 18 | 1 | -156 | 42 | 0 |
30 Sep 18 | 1 | -181 | 49 | 0 |
30 Jun 18 | 1 | -209 | 52 | 0 |
31 Mar 18 | 27 | -167 | 52 | 0 |
31 Dec 17 | 28 | -153 | 48 | 0 |
30 Sep 17 | 27 | -154 | 35 | 0 |
30 Jun 17 | 28 | -145 | 39 | 0 |
31 Mar 17 | 1 | -168 | 36 | 0 |
31 Dec 16 | 1 | -160 | 32 | 0 |
30 Sep 16 | 1 | -135 | 38 | 0 |
30 Jun 16 | 1 | -115 | 28 | 0 |
31 Mar 16 | 1 | -93 | 25 | 0 |
31 Dec 15 | 2 | -81 | 23 | 0 |
30 Sep 15 | 3 | -70 | 21 | 0 |
30 Jun 15 | 4 | -60 | 20 | 0 |
31 Mar 15 | 19 | -40 | 19 | 0 |
31 Dec 14 | 51 | -7 | 19 | 0 |
30 Sep 14 | 49 | -5 | 19 | 0 |
30 Jun 14 | 48 | -2 | 18 | 0 |
31 Mar 14 | 33 | -14 | 17 | 0 |
31 Dec 13 | 1 | -41 | 15 | 0 |
30 Sep 13 | 1 | -42 | 13 | 0 |
30 Jun 13 | 2 | -41 | 11 | 0 |
Quality Earnings: PRTA is currently unprofitable.
Growing Profit Margin: PRTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRTA is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.
Accelerating Growth: Unable to compare PRTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: PRTA has a negative Return on Equity (-26.19%), as it is currently unprofitable.